

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

Thank you for accessing STN

Our services are currently unavailable. The regularly scheduled hours of operations are:

US Eastern time: Sunday from 01:00 (1:00 AM) until
 Saturday at 22:00 (10:00 PM)

On the first Saturday of each month, STN is available only until 17:00 (5:00 PM).

Tokyo time: Sunday from 14:00 (2:00 PM) until
 Sunday at 11:00 (11:00 AM)

On the Sunday of the first weekend of each month, STN is available only until 06:00 (6:00 AM).

Additionally, representatives from the Help Desk and Customer Service may be reached from 08:00 (8:00 AM) to 20:00 (8:00 PM) US Eastern time, Monday through Friday, at the following telephone numbers:

Help Desk - (800) 848-6533 North America
 - (614) 447-3698 Elsewhere

Customer Service - (800) 753-4227 North America
 - (614) 447-3731 Elsewhere

We can also be contacted via email at HELP@CAS.ORG.

Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptl89dxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America

NEWS 2 JAN 02 STN pricing information for 2008 now available
 NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
 prophetic substances
 NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
 custom IPC display formats
 NEWS 5 JAN 28 MARPAT searching enhanced
 NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
 of publication
 NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements
 NEWS 9 FEB 08 STN Express, Version 8.3, now available
 NEWS 10 FEB 20 PCI now available as a replacement to DPCI
 NEWS 11 FEB 25 IFIREF reloaded with enhancements
 NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
 NEWS 13 FEB 29 WPINDEXT/WPIDS/WPIX enhanced with ECLA and current
 U.S. National Patent Classification
 NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
 IPC display formats
 NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental
 spectra
 NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S.
 applications updated
 NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
 NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:48:10 ON 13 APR 2008

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
 COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.21 | 0.21 |

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
 AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
 CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGS,
 DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:48:31 ON 13 APR 2008

69 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
 search error messages that display as 0* with SET DETAIL OFF.

=> s prevent?(p)scar? and (coat? or impreg?) and (bandage or gauze) and (ancrod or urokinase or streptokinase or phenobarbital or valproic acid)

0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
0* FILE BIOENG
0* FILE BIOTECHABS
0* FILE BIOTECHDS
0* FILE BIOTECHNO
1 FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN

17 FILES SEARCHED...

23 FILES SEARCHED...
0* FILE ESBIODASE
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
1 FILE IFIPAT
0* FILE KOSMET

43 FILES SEARCHED...
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
403 FILE USPATFULL

61 FILES SEARCHED...
69 FILE USPAT2
0* FILE WATER
2 FILE WPIDS
2 FILE WPINDEX

6 FILES HAVE ONE OR MORE ANSWERS, 69 FILES SEARCHED IN STNINDEX

L1 QUE PREVENT?(P) SCAR? AND (COAT? OR IMPREG?) AND (BANDAGE OR GAUZE) AND (A NCROD OR UROKINASE OR STREPTOKINASE OR PHENOBARBITAL OR VALPROIC ACID)

=> file caplus ifipat uspatfull uspat2

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 3.25 | 3.46 |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:51:27 ON 13 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 13:51:27 ON 13 APR 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPATFULL' ENTERED AT 13:51:27 ON 13 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:51:27 ON 13 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1

L2 474 L1

=> dup rem 12

PROCESSING COMPLETED FOR L2
L3 405 DUP REM L2 (69 DUPLICATES REMOVED)

=> s L3 and (ancrod or urokinase or streptokinase or valproic acid)
L4 383 L3 AND (ANCROD OR UROKINASE OR STREPTOKINASE OR VALPROIC ACID)

=> s L4 and (bandage or gauze)
L5 383 L4 AND (BANDAGE OR GAUZE)

=> s L4 and (bandage or gauze pad)
L6 151 L4 AND (BANDAGE OR GAUZE PAD)

=> s L6 and injury
L7 142 L6 AND INJURY

=> s L7 and first aid
L8 1 L7 AND FIRST AID

=> d L8 1

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:964610 CAPLUS

DN 141:401038

TI Ancrod irradiated, impregnated or coated
sutures and other first aid or wound management
bandaging materials for minimizing and/or preventing excessive
scar formation

IN Raffaniello, Samn

PA USA

SO U.S. Pat. Appl. Publ., 4 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 20040224006 | A1 | 20041111 | US 2004-829143 | 20040421 |
| PRAI | US 2003-464229P | P | 20030421 | | |

=> s L7 and prevent?(p)scar?
L9 142 L7 AND PREVENT?(P) SCAR?

=> s L9 and scarring
L10 136 L9 AND SCARRING

=> s L10 and prevent scarr?
L11 1 L10 AND PREVENT SCARR?

=> d L11 1

L11 ANSWER 1 OF 1 USPATFULL on STN

AN 2007:114745 USPATFULL

TI Methods and compositions for blocking platelet and cell adhesion, cell
migration and inflammation

IN Glidden, Paul F., San Diego, CA, UNITED STATES

PI US 2007099819 A1 20070503

AI US 2006-540203 A1 20060928 (11)

PRAI US 2005-721754P 20050928 (60)

DT Utility

FS APPLICATION

LN.CNT 2315

INCL INCLM: 514/002.000
 NCL NCLM: 514/002.000
 IC IPCI A61K0038-17 [I,A]
 IPCR A61K0038-17 [I,C]; A61K0038-17 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s L9 and coated bandage
 L12 0 L9 AND COATED BANDAGE

=> s L9 and coated(p)bandage?
 L13 20 L9 AND COATED(P) BANDAGE?

=> d l13 1-20

L13 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:964610 CAPLUS
 DN 141:401038
 TI Ancrod irradiated, impregnated or coated
 sutures and other first aid or wound management bandaging materials for
 minimizing and/or preventing excessive scar formation
 IN Raffaniello, Samn
 PA USA
 SO U.S. Pat. Appl. Publ., 4 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 20040224006 | A1 | 20041111 | US 2004-829143 | 20040421 |
| PRAI | US 2003-464229P | P | 20030421 | | |

L13 ANSWER 2 OF 20 USPATFULL on STN
 AN 2008:36416 USPATFULL
 TI THIOLATED MACROMOLECULES AND METHODS OF MAKING AND USING THEREOF
 IN Prestwich, Glenn D., Salt Lake City, UT, UNITED STATES
 Serban, Monica, Salt Lake City, UT, UNITED STATES
 PI US 2008031854 A1 20080207
 AI US 2007-776519 A1 20070711 (11)
 PRAI US 2006-806965P 20060711 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1841
 INCL INCLM: 424/093.100
 INCLS: 435/001.100; 435/325.000; 514/025.000; 530/350.000; 536/017.600;
 536/055.200
 NCL NCLM: 424/093.100
 NCLS: 435/001.100; 435/325.000; 514/025.000; 530/350.000; 536/017.600;
 536/055.200
 IC IPCI A61K0031-7008 [I,A]; A01N0001-02 [I,A]; A61K0045-00 [I,A];
 A61P0017-02 [I,A]; A61P0017-00 [I,C*]; A61P0041-00 [I,A];
 C07H0015-00 [I,A]; C07H0005-04 [I,A]; C07H0005-00 [I,C*];
 C07K0014-00 [I,A]; C12N0005-06 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 20 USPATFULL on STN
 AN 2007:257685 USPATFULL
 TI Sealants for Skin and Other Tissues
 IN Bowlin, Gary L., Mechanicsville, VA, UNITED STATES
 Simpson, David G., Mechanicsville, VA, UNITED STATES
 Wnek, Gary E., Cleveland, OH, UNITED STATES

Carr, Marcus E. JR., Holland, PA, UNITED STATES
Stevens, Peter J., N. Richland Hills, TX, UNITED STATES
Cadd, Gary, Grapevine, TX, UNITED STATES
Cohen, I. Kelman, Richmond, VA, UNITED STATES

PI US 2007225631 A1 20070927
AI US 2003-588344 A1 20031006 (10)
WO 2003-US31637 20031006
20070108 PCT 371 date

PRAI US 2002-416026P 20021004 (60)
US 2002-425949P 20021113 (60)

DT Utility
FS APPLICATION
LN.CNT 4946

INCL INCLM: 602/052.000
INCLS: 205/050.000; 530/356.000

NCL NCLM: 602/052.000
NCLS: 205/050.000; 530/356.000

IC IPCI A61F0013-00 [I,A]; A61K0038-17 [I,A]; C07K0001-00 [I,A]
IPCR A61F0013-00 [I,C]; A61F0013-00 [I,A]; A61K0038-17 [I,C];
A61K0038-17 [I,A]; C07K0001-00 [I,C]; C07K0001-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 20 USPATFULL on SIN

AN 2006:174046 USPATFULL
TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Tolcikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2006147492 A1 20060706

AI US 2006-343809 A1 20060131 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)

DT Utility
FS APPLICATION
LN.CNT 56233

INCL INCLM: 424/426.000

NCL NCLM: 424/426.000

IC IPCI A61F0002-00 [I,A]; A61K0031-47 [I,A]
IPCR A61F0002-00 [I,A]; A61F0002-00 [I,C]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0038-00 [I,C*];
A61K0038-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A];
A61M0016-04 [I,C*]; A61M0016-04 [I,A]; A61M0031-00 [I,C*];
A61M0031-00 [I,A]; A61N0001-05 [I,C*]; A61N0001-05 [I,A];
A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 20 USPATFULL on SIN

AN 2005:240095 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005208095 A1 20050922
 AI US 2004-996354 A1 20041122 (10)

RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)

DT Utility
 FS APPLICATION

LN.CNT 34089

INCL INCLM: 424/423.000

NCL NCLM: 424/423.000

IC [7]
 ICM A61F0002-00
 IPCI A61F0002-00 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-54 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 20 USPTFULL on STN

AN 2005:220596 USPTFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005191331 A1 20050901
 AI US 2004-1419 A1 20041130 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)

DT Utility
 FS APPLICATION

LN.CNT 56419

INCL INCLM: 424/423.000

NCL NCLM: 424/423.000

IC [7]
 ICM A61F0002-00
 IPCI A61F0002-00 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 20 USPATFULL on STN

AN 2005:220513 USPATFULL

TI Medical implants and fibrosis-inducing agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005191248 A1 20050901

AI US 2004-6907 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN.CNT 42940

INCL INCLM: 424/050.000

INCLS: 433/217.100

NCL NCLM: 424/050.000

NCLS: 433/217.100

IC [7]

ICM A61K007-28

ICS A61C005-00

IPCI A61K0007-28 [ICM,7]; A61C0005-00 [ICS,7]

IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];

A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];

A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];

A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];

A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];

A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];

A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];

A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];

A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];

A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];

A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];

A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];

A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];

A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];

A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];

A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];

A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];

A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];

A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 20 USPATFULL on STN

AN 2005:214575 USPATFULL

TI Medical implants and fibrosis-inducing agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005186247 A1 20050825
 AI US 2004-6904 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 43007
 INCL INCLM: 424/423.000
 NCL NCLM: 424/423.000
 IC [7]
 ICM A61F0002-00
 IPCI A61F0002-00 [ICM,7]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
 A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L13 ANSWER 9 OF 20 USPATFULL on STN
 AN 2005:212065 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.
 corporation)
 PI US 2005183728 A1 20050825
 AI US 2004-7836 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56413
 INCL INCLM: 128/207.140
 NCL NCLM: 128/207.140
 IC [7]
 ICM A61M016-04
 ICS A62B009-00
 IPCI A61M0016-04 [ICM,7]; A62B0009-00 [ICS,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
 L13 ANSWER 10 OF 20 USPATFULL on STN
 AN 2005:209494 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005181977 A1 20050818
 AI US 2004-986231 A1 20041110 (50)
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56396
 INCL INCLM: 514/002.000
 INCLS: 623/001.490
 NCL NCLM: 514/002.000
 NCLS: 623/001.490
 IC [7]
 ICM A61K038-00
 ICS A61F002-06
 IPCI A61K0038-00 [ICM,7]; A61F0002-06 [ICS,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 20 USPATFULL on STN
 AN 2005:208533 USPATFULL

TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005181011 A1 20050818
 AI US 2004-1792 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56421
 INCL INCLM: 424/423.000
 INCLS: 623/016.110
 NCL NCLM: 424/423.000
 NCLS: 623/016.110
 IC [7]
 ICM A61F002-28
 ICS A61F002-44
 IPCI A61F0002-28 [ICM,7]; A61F0002-44 [ICS,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 20 USPATFULL on STN
 AN 2005:208530 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005181008 A1 20050818
 AI US 2004-1786 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56377

INCL INCLM: 424/423.000
 INCLS: 604/500.000
 NCL NCLM: 424/423.000
 NCLS: 604/500.000
 IC [7]
 ICM A61F002-00
 ICS A61M031-00
 IPCI A61F0002-00 [ICM,7]; A61M0031-00 [ICS,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 20 USPATFULL on STN
 AN 2005:203799 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
 PI US 2005177225 A1 20050811
 AI US 2004-6895 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-518785P 20031110 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56371
 INCL INCLM: 623/001.420
 INCLS: 424/423.000; 623/011.110
 NCL NCLM: 623/001.420
 NCLS: 424/423.000; 623/011.110
 IC [7]
 ICM A61F002-02
 IPCI A61F0002-02 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 20 USPATFULL on STN
 AN 2005:202245 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005175663 A1 20050811
 AI US 2004-1791 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56451
 INCL INCLM: 424/423.000
 NCL NCLM: 424/423.000
 IC [7]
 ICM A61F0002-00
 IPCI A61F0002-00 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L13 ANSWER 15 OF 20 USPATFULL ON STN
 AN 2005:202239 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CA, UNITED STATES
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005175657 A1 20050811
 AI US 2004-4673 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 42820
 INCL INCLM: 424/422.000
 NCL NCLM: 424/422.000
 IC [7]
 ICM A61F0013-00
 IPCI A61F0013-00 [ICM,7]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];

A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 20 USPATFULL ON STN

AN 2005:195817 USPATFULL

TI Medical implants and fibrosis-inducing agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

PI US 2005169958 A1 20050804

AI US 2004-1420 A1 20041201 (11)

RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN.CNT 43012

INCL INCLM: 424/423.000

INCLS: 623/016.110

NCL NCLM: 424/423.000

NCLS: 623/016.110

IC [7]

ICM A61F002-28

IPCI A61F0002-28 [ICM,7]

IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];

A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];

A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];

A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];

A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];

A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];

A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];

A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];

A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];

A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];

A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];

A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];

A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 20 USPATFULL on STN

AN 2005:190568 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Teleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)

PI US 2005165488 A1 20050728

AI US 2004-6912 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DT Utility

FS APPLICATION

LN.CNT 56407

INCL INCLM: 623/017.160

NCL NCLM: 623/017.160

IC [7]

ICM A61F002-44

IPCI A61F0002-44 [ICM,7]

IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];

A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];

A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];

A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];

A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];

A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L13 ANSWER 18 OF 20 USPATFULL on STN

AN 2005:182891 USPATFULL

TI Medical implants and fibrosis-inducing agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Teleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005158274 A1 20050721

AI US 2004-6902 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 43022
 INCL INCLM: 424/078.380
 INCLS: 514/034.000; 514/055.000; 514/049.000; 514/251.000; 514/269.000
 NCL NCLM: 424/078.380
 NCLS: 514/034.000; 514/049.000; 514/055.000; 514/251.000; 514/269.000
 IC [7]
 ICM A61K031-765
 ICS A61K031-7072; A61K031-704; A61K031-513; A61K031-525
 IPCI A61K0031-765 [ICM,7]; A61K0031-74 [ICM,7,C*]; A61K0031-7072
 [ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-704 [ICS,7];
 A61K0031-7028 [ICS,7,C*]; A61K0031-513 [ICS,7]; A61K0031-525
 [ICS,7]; A61K0031-519 [ICS,7,C*]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
 A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 19 OF 20 USPATFULL ON STN
 AN 2005:172409 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005149158 A1 20050707
 AI US 2004-409 A1 20041129 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56404
 INCL INCLM: 607/119.000

NCL NCLM: 607/119.000
 IC [7]
 ICM A61N001-05
 IPCI A61N0001-05 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 20 OF 20 USPATFULL on STN
 AN 2005:172331 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005149080 A1 20050707
 AI US 2004-1418 A1 20041130 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-518785P 20031110 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56418
 INCL INCLM: 606/155.000
 NCL NCLM: 606/155.000
 IC [7]
 ICM A61F002-04
 IPCI A61F0002-04 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

=> s L9 and impreg?(p)bandag?
 L14 36 L9 AND IMPREG?(P) BANDAG?

=> d 114 1-36

L14 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:964610 CAPLUS
 DN 141:401038
 TI Anrod irradiated, impregnated or coated
 sutures and other first aid or wound management bandaging

materials for minimizing and/or preventing excessive
scar formation

IN Raffaniello, Samn

PA USA

SO U.S. Pat. Appl. Publ., 4 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 20040224006 | A1 | 20041111 | US 2004-829143 | 20040421 |
| PRAI | US 2003-464229P | P | 20030421 | | |

L14 ANSWER 2 OF 36 USPATFULL on SIN

AN 2007:342045 USPATFULL

TI Anti-scarring drug combinations and use thereof

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Grau, Daniel S., Arlington, MA, UNITED STATES

Borisy, Alexis, Arlington, MA, UNITED STATES

Keith, Curtis T., Boston, MA, UNITED STATES

Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

Nichols, M. James, Boston, MA, UNITED STATES

Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES

Serbedzija, George N., Sudbury, MA, UNITED STATES

PI US 2007299043 A1 20071227

AI US 2007-732808 A1 20070404 (11)

RLI Continuation-in-part of Ser. No. US 2006-542185, filed on 3 Oct 2006,
PENDING

PRAI US 2005-723053P 20051003 (60)

DT Utility

FS APPLICATION

LN.CNT 37332

INCL INCLM: 514/171.000

NCL NCLM: 514/171.000

IC IPCI A61K0031-57 [I,A]; A61P0017-02 [I,A]; A61P0017-00 [I,C*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 36 USPATFULL on SIN

AN 2007:237758 USPATFULL

TI Anti-scarring drug combinations and use thereof

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Grau, Daniel S., Arlington, MA, UNITED STATES

Borisy, Alexis, Arlington, MA, UNITED STATES

Keith, Curtis T., Boston, MA, UNITED STATES

Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

Nichols, M. James, Boston, MA, UNITED STATES

Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES

Serbedzija, George N., Sudbury, MA, UNITED STATES

PI US 2007208134 A1 20070906

AI US 2006-542185 A1 20061003 (11)

PRAI US 2005-723053P 20051003 (60)

DT Utility

FS APPLICATION

LN.CNT 37771

INCL INCLM: 525/054.100

NCL NCLM: 525/054.100

IC IPCI A61K0047-48 [I,A]

IPCR A61K0047-48 [I,C]; A61K0047-48 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 36 USPATFULL on SIN
AN 2007:68045 USPATFULL
TI Treatment for heart disease
IN Dinsmore, Jonathan H., Brookline, MA, UNITED STATES
Jacoby, Douglas B., Wellesley, MA, UNITED STATES
PI US 2007059288 A1 20070315
AI US 2006-394537 A1 20060331 (11)
PRAI US 2005-666932P 20050331 (60)
DT Utility
FS APPLICATION
LN.CNT 4110
INCL INCLM: 424/093.200
INCLS: 424/093.700; 514/002.000
NCL NCLM: 424/093.200
NCLS: 424/093.700; 514/002.000
IC IPCI A61K0048-00 [I,A]; A61K0035-14 [I,A]; A61K0038-17 [I,A]
IPCR A61K0048-00 [I,C]; A61K0048-00 [I,A]; A61K0035-14 [I,C];
A61K0035-14 [I,A]; A61K0038-17 [I,C]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 36 USPATFULL on SIN
AN 2006:174046 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2006147492 A1 20060706
AI US 2006-343809 A1 20060131 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LN.CNT 56233
INCL INCLM: 424/426.000
NCL NCLM: 424/426.000
IC IPCI A61F0002-00 [I,A]; A61K0031-47 [I,A]
IPCR A61F0002-00 [I,A]; A61F0002-00 [I,C]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0038-00 [I,C*];
A61K0038-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A];
A61M0016-04 [I,C*]; A61M0016-04 [I,A]; A61M0031-00 [I,C*];
A61M0031-00 [I,A]; A61N0001-05 [I,C*]; A61N0001-05 [I,A];
A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 36 USPATFULL on SIN
AN 2005:240095 USPATFULL

TI Polymer compositions and methods for their use
 IN Hunter, William L., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A. E., North Vancouver, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005208095 A1 20050922
 AI US 2004-996354 A1 20041122 (10)
 RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
 PENDING
 PRAI US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 34089
 INCL INCLM: 424/423.000
 NCL NCLM: 424/423.000
 IC [7]
 ICM A61F002-00
 IPCI A61F0002-00 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-54 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L14 ANSWER 7 OF 36 USPATFULL on STN
 AN 2005:226572 USPATFULL
 TI Polymer compositions and methods for their use
 IN Hunter, William L., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A. E., North Vancouver, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005196421 A1 20050908
 AI US 2004-1417 A1 20041201 (11)
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
 PENDING
 PRAI US 2004-611077P 20040917 (60)
 US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 34222
 INCL INCLM: 424/423.000
 INCL INCLS: 604/500.000
 NCL NCLM: 424/423.000
 NCL INCLS: 604/500.000
 IC [7]

ICM A61F0002-00
 ICS A61M0031-00
 IPCI A61F0002-00 [ICM,7]; A61M0031-00 [ICS,7]
 IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
 A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
 A61N0001-00 [I,C*]; A61N0001-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 8 OF 36 USPATFULL on STN

AN 2005:220596 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005191331 A1 20050901

AI US 2004-1419 A1 20041130 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN.CNT 56419

INCL INCLM: 424/423.000

NCL NCLM: 424/423.000

IC [7]

ICM A61F0002-00

IPCI A61F0002-00 [ICM,7]

IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];

A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];

A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];

A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];

A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];

A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 9 OF 36 USPATFULL on STN

AN 2005:220513 USPATFULL

TI Medical implants and fibrosis-inducing agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005191248 A1 20050901
 AI US 2004-6907 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 42940
 INCL INCLM: 424/050.000
 INCLS: 433/217.100
 NCL NCLM: 424/050.000
 NCLS: 433/217.100
 IC [7]
 ICM A61K007-28
 ICS A61C005-00
 IPCI A61K0007-28 [ICM,7]; A61C0005-00 [ICS,7]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
 A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 10 OF 36 USPATFULL on STN
 AN 2005:215464 USPATFULL
 TI Polymer compositions and methods for their use
 IN Hunter, William L., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A. E., North Vancouver, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005187140 A1 20050825
 AI US 2004-408 A1 20041129 (11)
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
 PENDING
 PRAI US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2004-611077P 20040917 (60)

US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)

DT Utility
 FS APPLICATION
 LN.CNT 34103
 INCL INCLM: 514/002.000
 INCLS: 623/017.110; 623/017.160; 606/076.000
 NCL NCLM: 514/002.000
 NCLS: 606/076.000; 623/017.110; 623/017.160
 IC [7]
 ICM A61K038-00
 ICS A61F002-44
 IPCI A61K0038-00 [ICM,7]; A61F0002-44 [ICS,7]
 IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
 A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
 A61N0001-00 [I,C*]; A61N0001-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 11 OF 36 USPATFULL on STN
 AN 2005:214575 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005186247 A1 20050825
 AI US 2004-6904 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)

DT Utility
 FS APPLICATION
 LN.CNT 43007
 INCL INCLM: 424/423.000
 NCL NCLM: 424/423.000
 IC [7]
 ICM A61F002-00
 IPCI A61F0002-00 [ICM,7]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
 A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];

A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 12 OF 36 USPATFULL ON STN

AN 2005:214572 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005186244 A1 20050825

AI US 2004-1790 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DT Utility

FS APPLICATION

LN.CNT 34060

INCL INCLM: 424/423.000

INCLS: 514/002.000; 514/034.000; 514/027.000; 514/283.000

NCL NCLM: 424/423.000

NCLS: 514/002.000; 514/027.000; 514/034.000; 514/283.000

IC [7]

ICM A61K031-7048

ICS A61K031-704; A61K031-4745

IPCI A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0031-704

[ICS,7]; A61K0031-7028 [ICS,7,C*]; A61K0031-4745 [ICS,7];

A61K0031-4738 [ICS,7,C*]

IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];

A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];

A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];

A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];

A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];

A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];

A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];

A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];

A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];

A61N0001-00 [I,C*]; A61N0001-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 13 OF 36 USPATFULL ON STN

AN 2005:212068 USPATFULL

TI Polymer compositions and methods for their use
 IN Hunter, William L., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A.E., North Vancouver, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005183731 A1 20050825
 AI US 2004-6908 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
 PENDING
 PRAI US 2004-611077P 20040917 (60)
 US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 34032
 INCL INCLM: 128/898.000
 INCLS: 623/013.110
 NCL NCLM: 128/898.000
 NCLS: 623/013.110
 IC [7]
 ICM A61B019-00
 ICS A61F002-08
 IPCI A61B0019-00 [ICM,7]; A61F0002-08 [ICS,7]
 IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
 A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
 A61N0001-00 [I,C*]; A61N0001-00 [I,A]
 L14 ANSWER 14 OF 36 USPATFULL on STN
 AN 2005:212065 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.
 corporation)
 PI US 2005183728 A1 20050825
 AI US 2004-7836 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56413
 INCL INCLM: 128/207.140
 NCL NCLM: 128/207.140
 IC [7]
 ICM A61M016-04
 ICS A62B009-00
 IPCI A61M0016-04 [ICM,7]; A62B0009-00 [ICS,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L14 ANSWER 15 OF 36 USPATFULL on STN
 AN 2005:209978 USPATFULL
 TI Polymer compositions and methods for their use
 IN Hunter, William L., Vancouver, CANADA
 Teleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A. E., North Vancouver, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
 PI US 2005182463 A1 20050818
 AI US 2004-1788 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2004-611077P 20040917 (60)
 US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 34070
 INCL INCLM: 607/115.000
 INCLS: 604/008.000; 623/011.110
 NCL NCLM: 607/115.000
 NCLS: 604/008.000; 623/011.110
 IC [7]
 ICM A61N001-00
 IPCI A61N0001-00 [ICM,7]
 IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
 A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];

A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
A61N0001-00 [I,C*]; A61N0001-00 [I,A]

L14 ANSWER 16 OF 36 USPATFULL on STN
AN 2005:209494 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Tolakis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181977 A1 20050818
AI US 2004-986231 A1 20041110 (10)
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LN.CNT 56396
INCL INCLM: 514/002.000
INCLS: 623/001.490
NCL NCLM: 514/002.000
NCLS: 623/001.490
IC [7]
ICM A61K038-00
ICS A61F002-06
IPCI A61K0038-00 [ICM,7]; A61F0002-06 [ICS,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 17 OF 36 USPATFULL on STN
AN 2005:208533 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Tolakis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181011 A1 20050818
AI US 2004-1792 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility
FS APPLICATION

LN.CNT 56421

INCL INCLM: 424/423.000

INCLS: 623/016.110

NCL NCLM: 424/423.000

NCLS: 623/016.110

IC [7]

ICM A61F002-28

ICS A61F002-44

IPCI A61F0002-28 [ICM,7]; A61F0002-44 [ICS,7]

IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];

A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];

A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];

A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];

A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];

A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 18 OF 36 USPATFULL on STN

AN 2005:208530 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005181008 A1 20050818

AI US 2004-1786 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN.CNT 56377

INCL INCLM: 424/423.000

INCLS: 604/500.000

NCL NCLM: 424/423.000

NCLS: 604/500.000

IC [7]

ICM A61F002-00

ICS A61M031-00

IPCI A61F0002-00 [ICM,7]; A61M0031-00 [ICS,7]

IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];

A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];

A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];

A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];

A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];

A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 19 OF 36 USPATFULL on STN
 AN 2005:205930 USPATFULL
 TI Polymer compositions and methods for their use
 IN Hunter, William L., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A. E., North Vancouver, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005178396 A1 20050818
 AI US 2004-6905 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
 PENDING
 PRAI US 2004-611077P 20040917 (60)
 US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 33965
 INCL INCLM: 128/898.000
 INCLS: 623/014.120
 NCL NCLM: 128/898.000
 NCLS: 623/014.120
 IC [7]
 ICM A61B019-00
 ICS A61F002-28
 IPCI A61B0019-00 [ICM,7]; A61F0002-28 [ICS,7]
 IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
 A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
 A61N0001-00 [I,C*]; A61N0001-00 [I,A]

L14 ANSWER 20 OF 36 USPATFULL on STN
 AN 2005:205929 USPATFULL
 TI Polymer compositions and methods for their use
 IN Hunter, William L., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 Takacs-Cox, Aniko, North Vancouver, CANADA
 Avelar, Rui, Vancouver, CANADA
 Loss, Troy A. E., North Vancouver, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005178395 A1 20050818
 AI US 2004-6900 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING

PRAI US 2004-611077P 20040917 (60)
 US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)

DT Utility
 FS APPLICATION
 LN.CNT 34043
 INCL INCLM: 128/898.000
 NCL NCLM: 128/898.000
 IC [7]
 ICM A61B019-00
 IPCI A61B0019-00 [ICM,7]
 IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
 A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
 A61N0001-00 [I,C*]; A61N0001-00 [I,A]

L14 ANSWER 21 OF 36 USPATFULL on STN
 AN 2005:203799 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
 PI US 2005177225 A1 20050811
 AI US 2004-6895 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-518785P 20031110 (60)

DT Utility
 FS APPLICATION
 LN.CNT 56371
 INCL INCLM: 623/001.420
 INCLS: 424/423.000; 623/011.110
 NCL NCLM: 623/001.420
 NCLS: 424/423.000; 623/011.110
 IC [7]
 ICM A61F0002-02
 IPCI A61F0002-02 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];

A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 22 OF 36 USPATFULL on STN

AN 2005:202285 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A.E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005175703 A1 20050811

AI US 2004-6888 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
PENDING

PRAI US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DT Utility

FS APPLICATION

LN.CNT 33992

INCL INCLM: 424/486.000

INCLS: 514/283.000; 514/449.000; 514/453.000

NCL NCLM: 424/486.000

NCLS: 514/283.000; 514/449.000; 514/453.000

IC [7]

ICM A61K031-4745

ICS A61K031-365; A61K031-337; A61K009-14

IPCI A61K0031-4745 [ICM,7]; A61K0031-4738 [ICM,7,C*]; A61K0031-365

[ICS,7]; A61K0031-337 [ICS,7]; A61K0009-14 [ICS,7]

IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];

A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];

A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];

A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];

A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];

A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];

A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];

A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];

A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];

A61N0001-00 [I,C*]; A61N0001-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 23 OF 36 USPATFULL on STN

AN 2005:202247 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005175665 A1 20050811
 AI US 2004-6896 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
 PENDING
 PRAI US 2004-611077P 20040917 (60)
 US 2004-586861P 20040709 (60)
 US 2004-566569P 20040428 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 33978
 INCL INCLM: 424/423.000
 INCLS: 514/034.000; 514/027.000; 514/283.000; 514/449.000; 514/049.000;
 514/575.000
 NCL NCLM: 424/423.000
 NCLS: 514/027.000; 514/034.000; 514/049.000; 514/283.000; 514/449.000;
 514/575.000
 IC [7]
 ICM A61K031-7048
 ICS A61K031-7072; A61K031-337; A61K031-704
 IPCI A61K0031-7048 [ICM,7]; A61K0031-7072 [ICS,7]; A61K0031-7042
 [ICS,7,C*]; A61K0031-337 [ICS,7]; A61K0031-704 [ICS,7];
 A61K0031-7028 [ICS,7,C*]
 IPCR A61B0019-00 [I,C*]; A61B0019-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
 A61K0031-337 [I,C*]; A61K0031-337 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
 A61N0001-00 [I,C*]; A61N0001-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L14 ANSWER 24 OF 36 USPATFULL on STN
 AN 2005:202245 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005175663 A1 20050811
 AI US 2004-1791 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 56451

INCL INCLM: 424/423.000
 NCL INCLM: 424/423.000
 IC [7]
 ICM A61F002-00
 IPCI A61F0002-00 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 25 OF 36 USPATFULL on STN
 AN 2005:202239 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CA, UNITED STATES
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005175657 A1 20050811
 AI US 2004-4673 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 42820
 INCL INCLM: 424/422.000
 NCL INCLM: 424/422.000
 IC [7]
 ICM A61F013-00
 IPCI A61F0013-00 [ICM,7]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
 A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 26 OF 36 USPATFULL on STN
 AN 2005:195818 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005169959 A1 20050804
 US 2006240063 A9 20061026
 AI US 2004-1421 A1 20041201 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 15682
 INCL INCLM: 424/423.000
 INCLS: 623/016.110
 NCL NCLM: 424/423.000
 NCLS: 623/016.110
 IC [7]
 ICM A61F0002-28
 IPCI A61F0002-28 [ICM,7]
 IPCI-2 A61F0002-28 [I,A]
 IPCR A61F0002-28 [I,C]; A61F0002-28 [I,A]; A61B0017-03 [I,C*];
 A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A];
 A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-00 [I,C*];
 A61F0002-00 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 27 OF 36 USPATFULL on STN
 AN 2005:195817 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

PI US 2005169958 A1 20050804

AI US 2004-1420 A1 20041201 (11)

RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN,CNT 43012

INCL INCLM: 424/423.000

INCLS: 623/016.110

NCL NCLM: 424/423.000

NCLS: 623/016.110

IC [7]

ICM A61F0002-28

IPCI A61F0002-28 [ICM,7]

IPCR A61B0017-03 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*]; A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*]; A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A]; A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*]; A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A]; A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*]; A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 28 OF 36 USPATFULL on STN

AN 2005:190568 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)

PI US 2005165488 A1 20050728

AI US 2004-6912 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DT Utility
FS APPLICATION
LN.CNT 56407
INCL INCLM: 623/017.160
NCL NCLM: 623/017.160
IC [7]
ICM A61F0002-44
IPCI A61F0002-44 [ICM,7]
IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L14 ANSWER 29 OF 36 USPATFULL on STN
AN 2005:182891 USPATFULL
TI Medical implants and fibrosis-inducing agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toliekis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005158274 A1 20050721
AI US 2004-6902 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

DT Utility
FS APPLICATION
LN.CNT 43022
INCL INCLM: 424/078.380
INCLS: 514/034.000; 514/055.000; 514/049.000; 514/251.000; 514/269.000
NCL NCLM: 424/078.380
NCLS: 514/034.000; 514/049.000; 514/055.000; 514/251.000; 514/269.000
IC [7]
ICM A61K031-765
ICS A61K031-7072; A61K031-704; A61K031-513; A61K031-525
IPCI A61K0031-765 [ICM,7]; A61K0031-74 [ICM,7,C*]; A61K0031-7072
[ICS,7]; A61K0031-7042 [ICS,7,C*]; A61K0031-704 [ICS,7];
A61K0031-7028 [ICS,7,C*]; A61K0031-513 [ICS,7]; A61K0031-525
[ICS,7]; A61K0031-519 [ICS,7,C*]
IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];

A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 30 OF 36 USPATFULL on STN

AN 2005:172409 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005149158 A1 20050707

AI US 2004-409 A1 20041129 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN.CNT 56404

INCL INCLM: 607/119.000

NCL NCLM: 607/119.000

IC [7]

ICM A61N001-05

IPCI A61N0001-05 [ICM,7]

IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];

A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];

A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];

A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];

A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];

A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];

A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 31 OF 36 USPATFULL on STN

AN 2005:172331 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005149080 A1 20050707

AI US 2004-1418 A1 20041130 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-518785P 20031110 (60)

DT Utility
 FS APPLICATION
 LN.CNT 56418
 INCL INCLM: 606/155.000
 NCL NCLM: 606/155.000
 IC [7]

ICM A61F0002-04
 IPCI A61F0002-04 [ICM,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [I,C*];
 A61F0002-02 [I,A]; A61F0002-04 [I,C*]; A61F0002-04 [I,A];
 A61F0002-06 [I,C*]; A61F0002-06 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61L0031-14 [I,C*];
 A61L0031-16 [I,A]; A61M0016-04 [I,C*]; A61M0016-04 [I,A];
 A61M0031-00 [I,C*]; A61M0031-00 [I,A]; A61N0001-05 [I,C*];
 A61N0001-05 [I,A]; A62B0009-00 [I,C*]; A62B0009-00 [I,A]

L14 ANSWER 32 OF 36 USPATFULL on STN
 AN 2005:171763 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005148512 A1 20050707
 AI US 2004-986230 A1 20041110 (10)
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)

DT Utility
 FS APPLICATION
 LN.CNT 42883
 INCL INCLM: 514/012.000
 INCLS: 514/055.000; 514/008.000; 514/053.000; 514/023.000; 514/154.000;
 514/724.000; 424/680.000; 424/085.100; 424/085.200

NCL NCLM: 514/012.000
 NCLS: 424/085.100; 424/085.200; 424/680.000; 514/008.000; 514/023.000;
 514/053.000; 514/055.000; 514/154.000; 514/724.000

IC [7]
 ICM A61K038-17
 ICS A61K031-7012; A61K031-70; A61K031-65; A61K031-045; A61K033-14;
 A61K038-19; A61K038-20; A61K038-18; A61K038-24
 IPCI A61K0038-17 [ICM,7]; A61K0031-7012 [ICS,7]; A61K0031-70 [ICS,7];
 A61K0031-65 [ICS,7]; A61K0031-045 [ICS,7]; A61K0033-14 [ICS,7];
 A61K0038-19 [ICS,7]; A61K0038-20 [ICS,7]; A61K0038-18 [ICS,7];
 A61K0038-24 [ICS,7]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
 A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];

A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 33 OF 36 USPATFULL on STN

AN 2005:170896 USPATFULL

TI Medical implants and fibrosis-inducing agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005147643 A1 20050707

US 7166570 B2 20070123

AI US 2004-6893 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN.CNT 43024

INCL INCLM: 424/423.000

INCLM: 514/012.000; 514/034.000; 514/283.000; 514/027.000; 514/251.000

NCL NCLM: 514/002.000; 424/423.000

NCLS: 530/353.000; 514/012.000; 514/027.000; 514/034.000; 514/251.000;

514/283.000

IC [7]

ICM A61K038-17

ICS A61K031-7048; A61K031-704; A61K031-4745

IPCI A61K0038-17 [ICM,7]; A61K0031-7048 [ICS,7]; A61K0031-7042

[ICS,7,C*]; A61K0031-704 [ICS,7]; A61K0031-7028 [ICS,7,C*];

A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]

IPCI-2 A61K0038-00 [I,A]; A61K0038-17 [I,A]

IPCR A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61B0017-03 [I,C*];

A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A];

A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-00 [I,C*];

A61F0002-00 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A];

A61F0013-00 [I,C*]; A61F0013-00 [I,A]; A61K0031-045 [I,C*];

A61K0031-045 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4745 [I,A];

A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-519 [I,C*];

A61K0031-525 [I,A]; A61K0031-65 [I,C*]; A61K0031-65 [I,A];

A61K0031-70 [I,C*]; A61K0031-70 [I,A]; A61K0031-7012 [I,C*];

A61K0031-7012 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A];

A61K0031-7042 [I,C*]; A61K0031-7048 [I,A]; A61K0031-7072 [I,A];

A61K0031-74 [I,C*]; A61K0031-765 [I,A]; A61K0033-14 [I,C*];

A61K0033-14 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A];
A61K0038-17 [I,C]; A61K0038-17 [I,A]; A61K0038-18 [I,C*];
A61K0038-18 [I,A]; A61K0038-19 [I,C*]; A61K0038-19 [I,A];
A61K0038-20 [I,C*]; A61K0038-20 [I,A]; A61K0038-24 [I,C*];
A61K0038-24 [I,A]; A61K0038-39 [I,C*]; A61K0038-39 [I,A];
A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0049-00 [I,C*];
A61K0049-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-00 [I,A];
A61L0027-54 [I,A]; A61L0031-00 [I,C*]; A61L0031-00 [I,A];
A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 34 OF 36 USPATFULL on STN

AN 2005:170852 USPATFULL

TI Medical implants and fibrosis-inducing agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005147599 A1 20050707

AI US 2004-6889 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LN,CNT 43016

INCL INCLM: 424/094.630

INCLS: 514/049.000; 514/251.000

NCL NCLM: 424/094.630

NCLS: 514/049.000; 514/251.000

IC [7]

ICM A61K038-48

ICS A61K031-525; A61K031-7072

IPCI A61K0038-48 [ICM,7]; A61K0038-43 [ICM,7,C*]; A61K0031-525

[ICS,7]; A61K0031-519 [ICS,7,C*]; A61K0031-7072 [ICS,7];

A61K0031-7042 [ICS,7,C*]

IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];

A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];

A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];

A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];

A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];

A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];

A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];

A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];

A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];

A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];

A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];

A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];

A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];

A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];

A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];

A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];

A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];

A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];

A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];

A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 35 OF 36 USPATFULL on STN
 AN 2005:170815 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005147562 A1 20050707
 AI US 2004-6886 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 43010
 INCL INCLM: 424/009.500
 INCLS: 424/423.000; 514/012.000; 514/027.000; 424/649.000; 514/283.000;
 514/251.000; 514/575.000
 NCL NCLM: 424/009.500
 NCLS: 424/423.000; 424/649.000; 514/012.000; 514/027.000; 514/251.000;
 514/283.000; 514/575.000
 IC [7]
 ICM A61K031-7048
 ICS A61K049-00; A61K038-17; A61K031-525; A61K031-4745; A61K033-24
 IPCI A61K0031-7048 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0049-00
 [ICS,7]; A61K0038-17 [ICS,7]; A61K0031-525 [ICS,7]; A61K0031-519
 [ICS,7,C*]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*];
 A61K0033-24 [ICS,7]
 IPCR A61B0017-03 [I,C*]; A61B0017-11 [I,A]; A61B0017-12 [I,C*];
 A61B0017-12 [I,A]; A61C0005-00 [I,C*]; A61C0005-00 [I,A];
 A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 36 OF 36 USPATFULL on STN
 AN 2005:164739 USPATFULL
 TI Medical implants and fibrosis-inducing agents
 IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005142163 A1 20050630
 US 2006240064 A9 20061026
 AI US 2004-1422 A1 20041201 (11)
 RLI Continuation of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)

DT Utility
 FS APPLICATION
 LN.CNT 34720
 INCL INCLM: 424/423.000
 NCL NCLM: 424/423.000
 IC [7]
 ICM A61F0002-00
 IPCI A61F0002-00 [ICM,7]
 IPCI-2 A61F0002-00 [I,A]
 IPCR A61F0002-00 [I,C]; A61F0002-00 [I,A]; A61B0017-03 [I,C*];
 A61B0017-11 [I,A]; A61B0017-12 [I,C*]; A61B0017-12 [I,A];
 A61C0005-00 [I,C*]; A61C0005-00 [I,A]; A61F0002-28 [I,C*];
 A61F0002-28 [I,A]; A61F0013-00 [I,C*]; A61F0013-00 [I,A];
 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-4738 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A];
 A61K0031-519 [I,C*]; A61K0031-525 [I,A]; A61K0031-65 [I,C*];
 A61K0031-65 [I,A]; A61K0031-70 [I,C*]; A61K0031-70 [I,A];
 A61K0031-7012 [I,C*]; A61K0031-7012 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0031-7072 [I,A]; A61K0031-74 [I,C*]; A61K0031-765 [I,A];
 A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-24 [I,C*];
 A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
 A61K0038-19 [I,A]; A61K0038-20 [I,C*]; A61K0038-20 [I,A];
 A61K0038-24 [I,C*]; A61K0038-24 [I,A]; A61K0038-39 [I,C*];
 A61K0038-39 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
 A61K0049-00 [I,C*]; A61K0049-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-54 [I,A]; A61L0031-00 [I,C*];
 A61L0031-00 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 111 3
 1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
 The answer numbers requested are not in the answer set.
 ENTER ANSWER NUMBER OR RANGE (1):
 ENTER ANSWER NUMBER OR RANGE (1):.

L11 ANSWER 1 OF 1 USPATFULL on STN
 AN 2007:114745 USPATFULL
 TI Methods and compositions for blocking platelet and cell adhesion, cell
 migration and inflammation
 IN Glidden, Paul F., San Diego, CA, UNITED STATES
 PI US 2007099819 A1 20070503
 AI US 2006-540203 A1 20060928 (11)
 PRAI US 2005-721754P 20050928 (60)
 DT Utility

FS APPLICATION
LN.CNT 2315
INCL INCLM: 514/002.000
NCL NCLM: 514/002.000
IC IPCI A61K0038-17 [I,A]
IPCR A61K0038-17 [I,C]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 114 3 ab

L14 ANSWER 3 OF 36 USPATFULL on STN
AB The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

=> d 114 3

L14 ANSWER 3 OF 36 USPATFULL on STN
AN 2007:237758 USPATFULL
TI Anti-scarring drug combinations and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisgy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES

PI US 2007208134 A1 20070906
AI US 2006-542185 A1 20061003 (11)
PRAI US 2005-723053P 20051003 (60)
DT Utility
FS APPLICATION
LN.CNT 37771
INCL INCLM: 525/054.100
NCL NCLM: 525/054.100
IC IPCI A61K0047-48 [I,A]
IPCR A61K0047-48 [I,C]; A61K0047-48 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 111 3

1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):.

L11 ANSWER 1 OF 1 USPATFULL on STN
AN 2007:114745 USPATFULL
TI Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
IN Glidden, Paul F., San Diego, CA, UNITED STATES

PI US 2007099819 A1 20070503
 AI US 2006-540203 A1 20060928 (11)
 PRAI US 2005-721754P 20050928 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2315
 INCL INCLM: 514/002.000
 NCL NCLM: 514/002.000
 IC IPCI A61K0038-17 [I,A]
 IPCR A61K0038-17 [I,C]; A61K0038-17 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L14 4

L14 ANSWER 4 OF 36 USPATFULL on STN
 AN 2007:68045 USPATFULL
 TI Treatment for heart disease
 IN Dinsmore, Jonathan H., Brookline, MA, UNITED STATES
 Jacoby, Douglas B., Wellesley, MA, UNITED STATES
 PI US 2007059288 A1 20070315
 AI US 2006-394537 A1 20060331 (11)
 PRAI US 2005-666932P 20050331 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4110
 INCL INCLM: 424/093.200
 INCLS: 424/093.700; 514/002.000
 NCL NCLM: 424/093.200
 NCLS: 424/093.700; 514/002.000
 IC IPCI A61K0048-00 [I,A]; A61K0035-14 [I,A]; A61K0038-17 [I,A]
 IPCR A61K0048-00 [I,C]; A61K0048-00 [I,A]; A61K0035-14 [I,C];
 A61K0035-14 [I,A]; A61K0038-17 [I,C]; A61K0038-17 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L14 3

L14 ANSWER 3 OF 36 USPATFULL on STN
 AN 2007:237758 USPATFULL
 TI Anti-scarring drug combinations and use thereof
 IN Hunter, William L., Vancouver, CANADA
 Teleikis, Philip M., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Grau, Daniel S., Arlington, MA, UNITED STATES
 Borisy, Alexis, Arlington, MA, UNITED STATES
 Keith, Curtis T., Boston, MA, UNITED STATES
 Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
 Nichols, M. James, Boston, MA, UNITED STATES
 Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
 Serbedzija, George N., Sudbury, MA, UNITED STATES
 PI US 2007208134 A1 20070906
 AI US 2006-542185 A1 20061003 (11)
 PRAI US 2005-723053P 20051003 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 37771
 INCL INCLM: 525/054.100
 NCL NCLM: 525/054.100
 IC IPCI A61K0047-48 [I,A]
 IPCR A61K0047-48 [I,C]; A61K0047-48 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 113 3

L13 ANSWER 3 OF 20 USPATFULL on STN
AN 2007:257685 USPATFULL
TI Sealants for Skin and Other Tissues
IN Bowlin, Gary L., Mechanicsville, VA, UNITED STATES
Simpson, David G., Mechanicsville, VA, UNITED STATES
Wnek, Gary E., Cleveland, OH, UNITED STATES
Carr, Marcus E. JR., Holland, PA, UNITED STATES
Stevens, Peter J., N. Richland Hills, TX, UNITED STATES
Cadd, Gary, Grapevine, TX, UNITED STATES
Cohen, I. Kelman, Richmond, VA, UNITED STATES
PI US 2007225631 A1 20070927
AI US 2003-588344 A1 20031006 (10)
WO 2003-US31637 20031006
20070108 PCT 371 date
PRAI US 2002-416026P 20021004 (60)
US 2002-425949P 20021113 (60)
DT Utility
FS APPLICATION
LN.CNT 4946
INCL INCLM: 602/052.000
INCLS: 205/050.000; 530/356.000
NCL NCLM: 602/052.000
NCLS: 205/050.000; 530/356.000
IC IPCI A61F0013-00 [I,A]; A61K0038-17 [I,A]; C07K0001-00 [I,A]
IPCR A61F0013-00 [I,C]; A61F0013-00 [I,A]; A61K0038-17 [I,C];
A61K0038-17 [I,A]; C07K0001-00 [I,C]; C07K0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 113 3 kwic

L13 ANSWER 3 OF 20 USPATFULL on STN
SUMM . . . strength and mechanical integrity (for example, sufficient integrity to withstand application of pressure to a sealant when used as a bandage). Many sealants involve the use of fibrin, a component of natural blood clots. Many sealants use the combination of fibrinogen. . .
SUMM . . . tissue or organs, and as sealants that can close, cover, obstruct, fill, or seal any type of leak, wound, ulcer, injury, opening, hole, or cavity. The sealants can be in the form of a matrix and can serve as matrices for. . .
SUMM . . . rapidly hemorrhaging wounds. In many embodiments, the use of the sealants of the present invention helps reduce the degree of scar formation in the location of use. In some embodiments, the compositions form a matrix, preferably a matrix similar to an. . .
embodiments, the sealant matrix has a pore size that is small enough to be impermeable to red blood cells, thus preventing leaking. In some embodiments, the sealant matrix has a pore size that is small enough to reduce or to eliminate. . .
SUMM . . . within the present invention. They are used as hemostatic agents to stop bleeding at the site of a wound or injury or at the site at which surgery has occurred or will occur. Tissue sealants are also used to create an. . . applied in any form. Some preferred forms include as a sheet or strip for direct application, a component of a bandage or gauze, and a powder or fluff that may be packed or sprinkled onto or into a location of a wound or injury. In some embodiments, the sealants are combined with water absorbent materials to provide water absorbency. Another use of

the electroprocessed. . .

SUMM . . . the present invention to provide sealants that can cover, obstruct, fill or seal one or more types of wound, ulcer, injury, hole, leak, cavity, enclosure, or opening in any tissue, organ, or part of any organism.

DRWD . . . of C are silver grains. The silver is present at irregular intervals in all implants due to use of a silver-impregnated dressing placed over the electrospun materials and the INTEGRA.

DETD . . . or agents that can prevent, reduce, or eliminate the flow of a fluid or can assist in repair of an injury or reinforcement of a tissue. The compositions are also used as adhesives for attaching tissues or structures of an organism. . . tissue or organs, and as sealants that can close, cover, obstruct, fill, or seal any type of leak, wound, ulcer, injury, opening, hole, or cavity. The sealants can be in the form of a matrix and can serve as matrices for. . .

DETD . . . any substance, composition, or object that can be used to cover, obstruct, fill, or seal any type of wound, ulcer, injury, hole, leak, cavity, enclosure, or opening in any tissue, organ or part of any organism as well as any composition. . .

DETD . . . such as sulfonated polyacrylamides are related materials, and electrical conductors such as carbon black, graphite, carbon nanotubes, metal particles, and metal-coated plastic or ceramic materials.

DETD . . . matrix components in some embodiments of tissue sealants. In some embodiments, substances that promote fibrinolysis (e.g. tissue plasminogen activator (TPA), urokinase, streptokinase) and/or substances that inhibit clotting (e.g. heparin, coumarin) are included to slow coagulation or to cause the clot to dissipate. . . clotting, and thus serve as a thrombin mimetic. Examples of this type of venom include, but are not limited to Ancrod (from the Malayan Pit Viper), Batroxobin (from Bothrops atrox), Crotalase (from the Eastern Diamondback), Venzyme (from the Southern Copperhead), and. . .

DETD . . . other openings and cavities. One use is as a hemostatic agent to stop bleeding at the site of a wound, injury, or other bleed. The sealants are used both internally (e.g. upon blood vessels, gut linings, and organs) and externally (e.g. . . any part of the body. In these embodiments the sealants serve, for example, as the sole component of a hemostatic bandage, as a component of a bandage that includes other elements such as adhesive backings, backings to provide a water barrier around the outside of the wound. . . also used as a treatment for ballistic injuries. Internal uses include, but are not limited to, arresting bleeding from an injury to an organ or blood vessel (for example, resulting from blunt abdominal trauma), perioperative bleeding and post-operative hemorrhage. Post surgical. . .

DETD . . . attached to the vessel. Matrices can also be used as plugs for leaks of cerebrospinal fluid, for example after spinal injury, spinal surgery, duraplasty, epidural anesthetic procedures, or other procedures that may lead to leakage. Yet another use is as an. . .

DETD . . . for use in tissue repair and support such as sutures, surgical and orthopedic screws, and surgical and orthopedic plates, natural coatings or components for synthetic implants, cosmetic implants and supports, repair or structural support for organs or tissues, substance delivery, bioengineering. . .

DETD The electroprocessed sealants are also used to support, reinforce, strengthen or connect tissue or structures that have experienced injury, surgery, or deterioration. For example, matrices can be used in a bladder neck suspension procedure for patients suffering from postpartum. . .

DETD . . . embodiment is use of substances and electroprocessed materials having an antibiotic and anti-inflammatory activity at the location of a

skin injury or treatment site for a skin infection.

DETD . . . applied in any form. Some preferred forms include as a sheet or strip for direct application, a component of a bandage or gauze, microdroplets that, for example, form from an electrospray process, a powder or fluff that may be packed or sprinkled onto or into a location of a wound or injury. In some embodiments, electroprocessed materials are ground or milled to produce fine powders which may be used directly or mixed. . . . Some embodiments include elastic electrospun materials, for example a sheet of the electroprocessed material that can be stretched over an injury and released, allowing residual tension to pull the open edges of a wound together. In some embodiments, applying an electroprocessed. . .

DETD used by one of ordinary skill in the art. Other embodiments involve electroprocessed matrices in a sheet serving as a bandage or otherwise packaged for easy use. Preferred unit dosage formulations are those containing a dose or unit, or an appropriate. . .

DETD that can occur with hemostatic agent or sealants in a liquid, gel, or semisolid state is the tendency for a gauze or bandage backing to absorb those sealants when pressure is applied. When this occurs, the sealant or hemostatic agent may adhere to the gauze or bandage and pull away from a wound or other site of application. In some embodiments, the sealants of the present invention remain sufficiently solid that they are not absorbed or otherwise attached to a bandage or gauze and thus do not pull away from a wound or other site of application when a bandage, gauze, or other backing is removed. The invention is not limited to solids and some embodiment have a consistency similar to. . .

DETD materials, and poly(1,5-dioxepan-2-one) and copolymers, thereof. Thus, embodiments include, for example, a highly flexible sealant or matrix placed on an injury site on the liver, a firmer, stiffer sealant or matrix used with bone injuries, and matrices containing a large amount. . .

DETD or circular shape, a rectangular envelope shape, a sheet, a ribbon, a cylinder, a plug to insert into a penetrating injury, a sleeve for placing around a vessel or duct, a nerve guide, skin or muscle patch, a dural patch, a powder, a fluff or batt, a bandage or gauze pad, a fascial sheath, vertebral disc, articular cartilage, knee meniscus, ligament, tendon, or a vascular graft for subsequent use in vivo. . . . This alignment allows the user to tear off strips of an electroprocessed material, for example to be used as a bandage. The matrix can be shaped to fit a defect or site to be filled, such as a site where a tumor has been removed, or an injury site in the skin (a cut, a biopsy site, a hole or other defect) or the location of a missing. . . tissue to be bioengineered. The target in some embodiments is a prosthetic, implant or other object that is to be coated with the electroprocessed material. Examples of coated objects include but are not limited to orthopedic implants or devices (e.g. bone screws, orthopedic spine cages, artificial hip joint. . .)

DETD initiator and oxidant (e.g., FeCl₃.sub.3). Finally, conducting polymers can be grown in the electroprocessed material after electroprocessing by using a matrix-coated conductor as the anode for electrochemical synthesis of, for example, polypyrrole or polyaniline. Materials to be electroprocessed can be added. . .

DETD Electroprocessed sealants are useful in formation of prostheses or for use in connection with prosthesis (e.g., as a coating or an adhesive). One application of the electroprocessed matrices is in the formation of medium and small diameter vascular prostheses. . .

DETD surface area to volume ratio. This is an important property in

some embodiments involving a hemostatic product such as a bandage in which the rate and extent of the coagulation in contact with the bandage in some embodiments are directly related to the surface area available for reaction with the blood components and thereby form. . .

DETD . . . unreacted glutaraldehyde, and then rinsed several times in sterile PBS supplemented with PenStrep antibiotics (Gibco) and cut to fit the injury sites. Each scaffolding was covered with a silver impregnated dressing and sutured in place. A bolster was fitted over the entire injury site to maintain gentle pressure on the dressings and inhibit wound contraction. At intervals the animals were sacrificed and the. . .

DETD (B) Electrospun collagen. The tongue was fully established at the margin of injury in wounds treated with electrospun collagen. (FIG. 8, Panel B) The formation of the epithelial tongue represents an important landmark. . .

DETD . . . Panel C). Scaffolds of electrospun VITROGEN also were densely populated with elongated dermal fibroblasts (arrowheads). At the margin of the injury, tongue formation was well established. Functional blood vessels were present within the matrix. Granulation tissue covered the entire wound site. . .

DETD (A) INTEGRA. Implants were infiltrated with dermal fibroblasts and tongue formation was evident at the margin of the injury site (FIG. 9, Panel A). The fibroblasts in the INTEGRA were scattered throughout the implanted matrix and did not exhibit. . .

DETD . . . Panel B, arrow). This epithelial layer lacked rete pegs (a histological feature of mature skin), but was continuous across the injury. The epidermis was multilayered and exhibited a well differentiated phenotype. A dense cell population appeared throughout the scaffold. The arrow. . .

DETD . . . above. FIG. 10 shows micrographs (20x) of the wound after seven days. Images were captured in the middle of the injury site just subjacent to free surface of implants (arrowheads denote free surface). The substance resting on the electrospun matrix of. . .

DETD . . . the heart. When a sheet electrospun from fibrinogen (approximately 1 cm by 1 cm) was placed onto this type of injury, it wet almost immediately and contracted onto the injury site. Excess blood that had pooled in the abdominal cavity was blotted with gauze and gentle pressure was applied by hand (fingertip) to the surface of the patch. When the pressure was relieved from the injury site blood was visible oozing outward from underneath the patch site. A second sheet of the same composition and dimensions. . .

DETD After 30-60 seconds a second puncture wound was prepared distal to the initial injury site. Arterial blood flow was evident from this puncture, demonstrating the patency of the aortic tree following treatment with the. . .

DETD . . . rather than a jet of blood). When a single patch of the electrospun fibrinogen was placed onto this type of injury site (1x1 cm square and 300-400 μ m thick) bleeding was stopped with the single sheet. . .

DETD . . . bleeding, although not as rapidly as the sheets of electrospun fibrinogen. A sheet of electrospun collagen applied to a spleen injury wetted nearly immediately and conformed to the shape of injury of the spleen and suppressed bleeding. Similar results were obtained with injuries to the liver. However, sheets of electrospun collagen. . .

DETD . . . A single sheet of electrospun fibrinogen (2 cm in lengthx1.2 cm in widthx300-500 μ m thick) was applied over the injury and compressed for 10 seconds with gentle pressure. The injury remained sealed after releasing pressure for 20 seconds, and the heart continued to contract vigorously. A small

amount of seepage. . . all bleeding stopped. After an additional minute the sheet was removed. A clot was evident around the aorta in the injury site and no additional bleeding was evident even after removal of the sheet. Puncturing the Aorta distal to the initial injury site resulted in a fresh jet of arterial blood. This jet of blood demonstrates the patency of the vessel and. . . that perfusion pressures at the site of the clot were substantial and sufficient to support vigorous bleeding if the original injury site had not been completely sealed by the treatment.

DETD . . . were made by transection of the spleen with scissors. In both cases, the electroprocessed collagen material was applied after the injury with forceps directly to the wound surface. For some liver injuries, the wound was larger than the electroprocessed material, so. . .

CLM What is claimed is:

14. A method of providing physical reinforcement to tissue, repairing an injury or defect in tissue, promoting healing or causing hemostasis comprising applying the composition of claim 1 to tissue requiring physical. . .

=>

Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspt189dxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|------|----|--------|---|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | NOV 21 | CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present |
| NEWS | 3 | NOV 26 | MARPAT enhanced with FSORT command |
| NEWS | 4 | NOV 26 | MEDLINE year-end processing temporarily halts availability of new fully-indexed citations |
| NEWS | 5 | NOV 26 | CHEMSAFE now available on STN Easy |
| NEWS | 6 | NOV 26 | Two new SET commands increase convenience of STN searching |
| NEWS | 7 | DEC 01 | ChemPort single article sales feature unavailable |
| NEWS | 8 | DEC 12 | GBFULL now offers single source for full-text coverage of complete UK patent families |
| NEWS | 9 | DEC 17 | Fifty-one pharmaceutical ingredients added to PS |
| NEWS | 10 | JAN 06 | The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo |
| NEWS | 11 | JAN 07 | WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 22:51:49 ON 19 JAN 2009

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.22 | 0.22 |

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 22:52:11 ON 19 JAN 2009

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s scar? and defibrino? and bandage?

1 FILE CAPLUS
1 FILE IFIPAT
59 FILES SEARCHED...
2 FILE USPATFULL
1 FILE WPIDS
1 FILE WPINDEX

5 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L1 QUE SCAR? AND DEFIBRINO? AND BANDAGE?

=> file caplus ifipat uspatfull

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.68 | 0.90 |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 22:53:02 ON 19 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 22:53:02 ON 19 JAN 2009
COPYRIGHT (C) 2009 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPATFULL' ENTERED AT 22:53:02 ON 19 JAN 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1

L2 4 L1

=> rem dup l2
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

| | |
|------------------------|--|
| DELETE BIO?/Q | - delete query names starting with BIO |
| DELETE ?DRUG/A | - delete answer set names ending with DRUG |
| DELETE ?ELEC?/L | - delete L-number lists containing ELEC |
| DELETE ANTICOG/S | - delete SDI request |
| DELETE ENZYME/B | - delete batch request |
| DELETE .MYCLUSTER | - delete user-defined cluster |
| DELETE .MYFORMAT | - delete user-defined display format |
| DELETE .MYFIELD | - delete user-defined search field |
| DELETE NAMELIST MYLIST | - delete mailing list |

To delete an ordered document or an offline print, enter its number.

Examples:

| | |
|-----------------|---------------------------------|
| DELETE P123001C | - delete print request |
| DELETE D134002C | - delete document order request |

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

| | |
|-----------------------|--|
| DELETE L21 | - delete a single L-number |
| DELETE L3-L6 | - delete a range of L-numbers |
| DELETE LAST 4 | - delete the last 4 L-numbers |
| DELETE L33- | - delete L33 and any higher L-number |
| DELETE -L55 | - delete L55 and any lower L-number |
| DELETE L2-L6 RENUMBER | - delete a range of L-numbers and renumber remaining L-numbers |
| DELETE RENUMBER | - renumber L-numbers after deletion of intermediate L-numbers |

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

| | |
|----------------|---|
| DELETE SAVED/Q | - delete all saved queries |
| DELETE SAVED/A | - delete all saved answer sets |
| DELETE SAVED/L | - delete all saved L-number lists |
| DELETE SAVED | - delete all saved queries, answer sets, and L-number lists |
| DELETE SAVED/S | - delete all SDI requests |
| DELETE SAVED/B | - delete all batch requests |
| DELETE CLUSTER | - delete all user-defined clusters |

```

DELETE FORMAT - delete all user-defined display formats
DELETE FIELD - delete all user-defined search fields
DELETE SELECT - delete all E-numbers
DELETE HISTORY - delete all L-numbers and restart the
                  session at L1

```

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

```

=> dup reml2
ENTER REMOVE, IDENTIFY, ONLY, OR (?):.
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):.
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):r
'R' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):id
'ID' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):.
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
YOU HAVE RECEIVED THIS PROMPT MESSAGE 5 CONSECUTIVE TIMES WITHOUT ENTERING A
REQUESTED RESPONSE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
ENTER REMOVE, IDENTIFY, ONLY, OR (?):
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):end

```

```

=> d hist

```

(FILE 'HOME' ENTERED AT 22:51:49 ON 19 JAN 2009)

```

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,

```

DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 22:52:11 ON 19 JAN 2009
SEA SCAR? AND DEFIBRINO? AND BANDAGE?

```
-----  
1   FILE CAPLUS  
1   FILE IFIPAT  
2   FILE USPATFULL  
1   FILE WPIDS  
1   FILE WPINDEX  
L1  QUE SCAR? AND DEFIBRINO? AND BANDAGE?  
-----
```

FILE 'CAPLUS, IFIPAT, USPATFULL' ENTERED AT 22:53:02 ON 19 JAN 2009

L2 4 S L1

=> rem dup l2

DUP IS NOT VALID HERE

The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

| | |
|------------------------|--|
| DELETE BIO?/Q | - delete query names starting with BIO |
| DELETE ?DRUG/A | - delete answer set names ending with DRUG |
| DELETE ?ELEC?/L | - delete L-number lists containing ELEC |
| DELETE ANTICOAG/S | - delete SDI request |
| DELETE ENZYME/B | - delete batch request |
| DELETE .MYCLUSTER | - delete user-defined cluster |
| DELETE .MYFORMAT | - delete user-defined display format |
| DELETE .MYFIELD | - delete user-defined search field |
| DELETE NAMELIST MYLIST | - delete mailing list |

To delete an ordered document or an offline print, enter its number.

Examples:

| | |
|-----------------|---------------------------------|
| DELETE P123001C | - delete print request |
| DELETE D134002C | - delete document order request |

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

| | |
|-----------------------|--|
| DELETE L21 | - delete a single L-number |
| DELETE L3-L6 | - delete a range of L-numbers |
| DELETE LAST 4 | - delete the last 4 L-numbers |
| DELETE L33- | - delete L33 and any higher L-number |
| DELETE -L55 | - delete L55 and any lower L-number |
| DELETE L2-L6 RENUMBER | - delete a range of L-numbers and renumber remaining L-numbers |
| DELETE RENUMBER | - renumber L-numbers after deletion of intermediate L-numbers |

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

```
DELETE SAVED/Q - delete all saved queries
DELETE SAVED/A - delete all saved answer sets
DELETE SAVED/L - delete all saved L-number lists
DELETE SAVED - delete all saved queries, answer sets,
                and L-number lists
DELETE SAVED/S - delete all SDI requests
DELETE SAVED/B - delete all batch requests
DELETE CLUSTER - delete all user-defined clusters
DELETE FORMAT - delete all user-defined display formats
DELETE FIELD - delete all user-defined search fields
DELETE SELECT - delete all E-numbers
DELETE HISTORY - delete all L-numbers and restart the
                session at L1
```

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

```
=> dup rem l2
PROCESSING COMPLETED FOR L2
L3          2 DUP REM L2 (2 DUPLICATES REMOVED)
```

```
=> d l3 1-2
```

```
L3  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN  DUPLICATE 1
AN  2004:964610  CAPLUS
DN  141:401038
TI  Ancrod irradiated, impregnated or coated sutures and other first aid or
    wound management bandaging materials for minimizing and/or preventing
    excessive scar formation
IN  Raffaniello, Samn
PA  USA
SO  U.S. Pat. Appl. Publ., 4 pp.
    CODEN: USXXCO
DT  Patent
LA  English
FAN.CNT 1
```

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 20040224006 | A1 | 20041111 | US 2004-829143 | 20040421 |
| PRAI | US 2003-464229P | P | 20030421 | | |

```
L3  ANSWER 2 OF 2  USPATFULL on STN
AN  2003:319606  USPATFULL
TI  Composite material for wound repair
IN  Butler, Charles E., Houston, TX, UNITED STATES
PI  US 20030225355  A1  20031204
AI  US 2003-406153  A1  20030401 (10)
RLI  Continuation-in-part of Ser. No. US 1998-164481, filed on 1 Oct 1998,
     PENDING
PRAI US 2002-369063P  20020401 (60)
DT  Utility
FS  APPLICATION
LN.CNT 1283
INCL INCLM: 602/048.000
NCL  NCLM: 602/048.000
IC  [7]
```

ICM A61F013-00
 ICS A61F015-00
 IPCI A61F0013-00 [ICM,7]; A61F0015-00 [ICS,7]
 IPCR A61F0002-00 [I,C*]; A61F0002-00 [I,A]; A61F0002-02 [N,C*];
 A61F0002-02 [N,A]; A61F0002-28 [N,C*]; A61F0002-28 [N,A];
 A61F0002-30 [N,C*]; A61F0002-30 [N,A]; A61L0027-00 [I,C*];
 A61L0027-36 [I,A]; A61L0027-38 [I,A]; A61L0027-48 [I,A];
 A61L0031-12 [I,C*]; A61L0031-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 13 1 ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1
 AB A method for minimizing scarring and preventing excessive scar formation at an injury site is disclosed. The method involves the topical and/or local application of a therapeutically effective amount of a defibrinogenating agent or of a fibrinolytic agent that may be delivered in an appropriate vehicle in a controlled- or timed-release manner. The defibrinogenating agent or fibrinolytic agent is applied as a coating on, or is irradiated or impregnated into or onto a delivery vehicle such as, for example, sutures, dissolvable sutures, bandages, gauze pads, or other types of first aid bandaging materials. Such application may take the form of a controlled- or timed-release aspect of either the vehicle, the delivery material or the therapeutic agent, such that the release of the therapeutic agent may be regulated to produce an appropriate therapeutic pattern of defibrinogenation or fibrinolysis. In a preferred aspect of the invention, the defibrinogenating agent is anacrod, and the mode of application is as anacrod-coated sutures.

=> d 13 2 ab

L3 ANSWER 2 OF 2 USPATFULL on STN
 AB A composite comprising a barrier material and a support material used for wound or tissue repair. Benefits include decreased adhesion to organs or other structures adjacent to the repair site, limited fluid flux, increased vascularization and cellular infiltration, decreased inflammation and reduced scar tissue formation.

=> d hist

(FILE 'HOME' ENTERED AT 22:51:49 ON 19 JAN 2009)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTE, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 22:52:11 ON 19 JAN 2009
 SEA SCAR? AND DEFIBRINO? AND BANDAGE?

 1 FILE CAPLUS
 1 FILE IFIPAT
 2 FILE USPATFULL
 1 FILE WPIDS
 1 FILE WPINDEX

L1 QUE SCAR? AND DEFIBRINO? AND BANDAGE?

FILE 'CAPLUS, IFIPAT, USPATFULL' ENTERED AT 22:53:02 ON 19 JAN 2009

L2 4 S L1

L3

2 DUP REM L2 (2 DUPLICATES REMOVED)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

17.80

18.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.82

-0.82

STN INTERNATIONAL LOGOFF AT 22:56:34 ON 19 JAN 2009